Garcia-de la Virgen Miguel, Del Portillo Miguel Isabel, Maiques Elisa, Pérez Roger Ignacio, Poch Enric, Borrego Juan
Oncology Service, Hospital Aúna Especialidades Veterinarias, IVC Evidensia, 46980 Paterna, Valencia, Spain.
The Hospital for Small Animals, The Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Edinburgh EH8 9YL, UK.
Vet Sci. 2024 Sep 13;11(9):430. doi: 10.3390/vetsci11090430.
Canine inflammatory mammary carcinoma (IMC) is an aggressive and rare type of mammary gland cancer in dogs where vascular endothelial growth factor and cyclooxigenase-2 overexpression usually occur, which contribute to its invasive and angiogenic nature. This study aimed to evaluate the efficacy and safety of a combined treatment regimen of toceranib phosphate and carprofen in dogs with measurable IMC. Fifteen female dogs with histopathologically confirmed IMC were included, undergoing a regimen of toceranib (2.4-2.75 mg/kg PO, three times weekly) and carprofen (4.4 mg/kg/24 h PO). Initial evaluations included physical exams, tumor measurements, complete blood count, biochemistry, urinalysis, three view thoracic radiographs, and abdominal ultrasound. Follow-up assessments of physical condition and quality of life (QOL) were conducted bi-weekly, with tumor response evaluations monthly, using RECIST v1.0 criteria. While no complete or partial responses were observed, 60% of the dogs maintained stable disease, with a median progression-free survival of 76 days and an overall survival of 90 days. Notably, 60% of the dogs showed clinical benefit through improved QOL and disease stabilization. The treatment was well-tolerated, with only grade I/II toxicities reported. Despite limited biological activity against the cancer, this protocol may enhance QOL in dogs with IMC, offering a valuable palliative option.
犬炎性乳腺癌（IMC）是一种侵袭性且罕见的犬类乳腺癌，通常会出现血管内皮生长因子和环氧化酶-2过表达，这促成了其侵袭性和血管生成特性。本研究旨在评估磷酸托西拉尼和卡洛芬联合治疗方案对可测量的犬IMC的疗效和安全性。纳入了15只经组织病理学确诊为IMC的雌性犬，接受托西拉尼（2.4 - 2.75 mg/kg口服，每周三次）和卡洛芬（4.4 mg/kg/24小时口服）的治疗方案。初始评估包括体格检查、肿瘤测量、全血细胞计数、生化检查、尿液分析、胸部三联X光片和腹部超声检查。每两周进行一次身体状况和生活质量（QOL）的随访评估，每月使用RECIST v1.0标准进行肿瘤反应评估。虽然未观察到完全缓解或部分缓解，但60%的犬病情稳定，无进展生存期的中位数为76天，总生存期为90天。值得注意的是，60%的犬通过改善生活质量和病情稳定显示出临床获益。该治疗耐受性良好，仅报告了I/II级毒性。尽管对癌症的生物学活性有限，但该方案可能会提高IMC犬的生活质量，提供一种有价值的姑息治疗选择。
